Tienopiridinas: interacción con otros fármacos, mas allá de las evidencias

jueves1255ussaillant
Gastón Dussaillant
2011-05-12

More articles by this author

Evaluación funcional vs anatómica de lesiones coronarias

Luis Mercado 2011-05-12

Evaluación de la placa vulnerable

Gastón Dussaillant2011-05-12

Pacientes de alto riesgo: triple terapia? – riesgo asociado

José Mangione2011-05-12

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...